Efficacy of Leflunomide Compared to Methotrexate in the Treatment of Moderate to Severe Plaques Psoriasis: A Randomized Controlled Clinical Trial
Keywords:
psoriasis, PASI, methotrexate, leflunomide, AvaraAbstract
Introduction: Psoriasis is a chronic inflammatory autoimmune skin disease. Several treatment options are available including topical and systemic options. Methotrexate was the main systemic medication in treating severe psoriasis, yet adverse events can limit its use. Leflunomide is an isoxazole derivative that inhibits the synthesis of pyrimidines, and subsequently inhibits RNA and DNA synthesis.
Objective: As available data directly comparing MTX to leflunomide in psoriasis are lacking, this double blinded study was designed to compare the efficacy of methotrexate versus leflunomide in the treatment of moderate to severe psoriasis.
Methods: The study included 40 patients (25 males and 15 females) with chronic plaque psoriasis, s. Patients were randomly assigned to one of two equal groups, group A for subcutaneous methotrexate injections and group B for leflunomide (loading dose 100mg daily for the first 3 days then 20 mg daily for 3 months. Disease severity was determined by psoriasis area and severity index (PASI) score before and at the end of treatment The treatment response was evaluated at the baseline and weeks 4, 8 and 12 PASI score.
Results: Both groups were matching at the baseline in aspects of gender, age, disease duration and PASI scores Both medications yielded comparable results with no significant difference between both groups in PASI score neither in side effects..
Conclusion: Leflunomide can be as effective as methotrexate in treatment of moderate to severe psoriasis.
References
Schwartzman M, Abutalib Z, Mandl LA. Current Medication Practices and Preferences Among Patients With Psoriatic Arthritis. J Clin Rheumatol. 2022 Mar 1;28(2):55-61. doi: 10.1097/RHU.0000000000001799.
Walter K. Psoriasis. JAMA. 2022 May 17;327(19):1936. doi: 10.1001/jama.2022.5270.
Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol. 2022 Jun 10;13:880201. doi: 10.3389/fimmu.2022.880201.
Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: A review. J Dermatol. 2021 Jun;48(6):722-731. doi: 10.1111/1346-8138.15913. Epub 2021 Apr 22. PMID: 33886133.
Dhabale A, Nagpure S. Types of Psoriasis and Their Effects on the Immune System. Cureus. 2022 Sep 24;14(9):e29536. doi: 10.7759/cureus.29536.
Yang EJ, Beck KM, Sanchez IM, Koo J, Liao W. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl). 2018 Aug 28;8:41-47. doi: 10.2147/PTT.S169389.
Burden AD, Choon SE, Gottlieb AB, Navarini AA, Warren RB. Clinical Disease Measures in Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022 Jan;23(Suppl 1):39-50. doi: 10.1007/s40257-021-00653-0.
Perez-Chada LM, Cohen JM, Gottlieb AB, et al. Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. Arch Dermatol Res. 2018 Nov;310(9):701-710. doi: 10.1007/s00403-018-1855-3.
Schadler ED, Ortel B, Mehlis SL. Biologics for the primary care physician: Review and treatment of psoriasis. Dis Mon. 2019 Mar;65(3):51-90. doi: 10.1016/j.disamonth.2018.06.001.
van Huizen AM, Sikkel R, Caron AGM, Menting SP, Spuls PI. Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review. J Dermatolog Treat. 2022 Dec;33(8):3104-3118. doi: 10.1080/09546634.2022.2117539. Epub 2022 Sep 9. PMID: 36043844.
Puig L. Methotrexate: new therapeutic approaches. Actas Dermosifiliogr. 2014 Jul-Aug;105(6):583-9. English, Spanish. doi: 10.1016/j.ad.2012.11.017.
Weidmann A, Foulkes AC, Kirkham N, Reynolds NJ. Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature. Dermatol Ther (Heidelb). 2014 Dec;4(2):145-56. doi: 10.1007/s13555-014-0056-z. Epub 2014 Jun 19. PMID: 24942326; PMCID: PMC4257944.
Xue H, Ci X, Luo M, Wu L, Du X, Li L, Lu X. Tofacitinib combined with leflunomide for treatment of psoriatic arthritis with IgA nephropathy: a case report with literature review. Clin Rheumatol. 2022 Jul;41(7):2225-2231. doi: 10.1007/s10067-022-06113-2.
Haroon M, Batool S, Asif S, Hashmi F, Ullah S. Combination of Methotrexate and Leflunomide Is Safe and Has Good Drug Retention Among Patients With Psoriatic Arthritis. J Rheumatol. 2021 Oct;48(10):1624-1626. doi: 10.3899/jrheum.201408.
Mulder MLM, Vriezekolk JE, den Broeder N, et al. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA). The Lancet Rheumatol 2022; 4: e252-e261
Alabas OA, Mason KJ, Yiu ZZN, et al; BADBIR Study Group. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. Br J Dermatol. 2023 Apr 20;188(5):618-627. doi: 10.1093/bjd/ljad004. PMID: 36763783.
Affleck AG, Williams H. Is leflunomide effective in the treatment of psoriasis in a patient who is unable to benefit from standard first- and second-line therapies and needs an affordable treatment option? Arch Dermatol. 2008 Dec;144(12):1642-3. doi: 10.1001/archdermatol.2008.502.
Kaltwasser JP, Nash P, Gladman D, et al; Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2004 Jun;50(6):1939-50. doi: 10.1002/art.20253.
Tlacuilo-Parra JA, Guevara-Gutiérrez E, Rodríguez-Castellanos MA, Ornelas-Aguirre JM, Barba-Gómez JF, Salazar-Páramo M. Leflunomide in the treatment of psoriasis: results of a phase II open trial. Br J Dermatol. 2004 May;150(5):970-6. doi: 10.1111/j.1365-2133.2004.05836.x. PMID: 15149511
Nash P, Thaçi D, Behrens F, Falk F, Kaltwasser JP. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology. 2006;212(3):238-49. doi: 10.1159/000091251.
Thami GP, Garg G. Leflunomide in psoriasis and psoriatic arthritis: a preliminary study. Arch Dermatol. 2004 Oct;140(10):1288-9. doi: 10.1001/archderm.140.10.1288.
Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthritis. J Clin Rheumatol. 2001 Dec;7(6):366-70. doi: 10.1097/00124743-200112000-00003.
Behrens F, Finkenwirth C, Pavelka K, Štolfa J, Šipek-Dolnicar A, Thaçi D, Burkhardt H. Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken). 2013 Mar;65(3):464-70. doi: 10.1002/acr.21848.
Hsieh TS, Tsai TF. Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review. Dermatol Ther (Heidelb). 2023 Apr;13(4):891-909. doi: 10.1007/s13555-023-00903-5.
Mazhar F, Krantz Å, Schalin L, Lysell J, Carrero JJ. Occurrence of adverse events associated with the initiation of methotrexate and biologics for the treatment of psoriasis in routine clinical practice. J Dermatolog Treat. 2023;34(1):2215354. doi: 10.1080/09546634.2023.2215354.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Hany Aboelwafa, Hassan Abokhodeir, Doaa Mamdouh Ibrahim, Nermeen Ibrahim Bedair
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.